Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.07 USD
Change Today +0.0298 / 1.46%
Volume 90.5K
As of 8:10 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

biolife solutions inc (BLFS) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/22/14 - $3.89
52 Week Low
04/1/15 - $1.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOLIFE SOLUTIONS INC (BLFS)

Related News

No related news articles were found.

biolife solutions inc (BLFS) Related Businessweek News

No Related Businessweek News Found

biolife solutions inc (BLFS) Details

BioLife Solutions, Inc. develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions for cells and tissues in the United States. The company’s products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, delayed-onset cell damage, and death. It offers HypoThermosol FRS, a hypothermic storage and shipping media product to reduce post-preservation necrosis and apoptosis; and PrepaStor, a flush solution designed for use during the transitions from normothermic to mild hypothermic conditions to rinse culture media and native fluids from tissue and whole organ systems prior to suspension in a preservation solution. The company also provides CryoStor cryopreservation freeze media products, which are designed to mitigate temperature-induced molecular cell stress responses during freezing and thawing; and BloodStor products comprising BloodStor 55-5 and BloodStor 100 for cryopreservation of cells isolated from umbilical cord blood, peripheral blood, and bone marrow. In addition, it offers SAVSU precision thermal packaging products; custom product formulation and custom packaging services; and contract aseptic manufacturing formulation, fill, and finish services of liquid media products. The company markets its products to the bio banking, drug discovery, and regenerative medicine markets, including hospital-based stem cell transplant centers, pharmaceutical companies, cord blood and adult stem cell banks, hair transplant centers, and suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. BioLife Solutions, Inc. was founded in 1987 and is based in Bothell, Washington.

38 Employees
Last Reported Date: 03/12/15
Founded in 1987

biolife solutions inc (BLFS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $450.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $213.8K
Chairman of Scientific Advisory Board, Chief ...
Total Annual Compensation: $239.8K
Compensation as of Fiscal Year 2013.

biolife solutions inc (BLFS) Key Developments

Cord Blood Registry Uses BioLife Solutions CryoStor Clinical Grade Freeze Media in the Storage of Umbilical Cord Tissue Stem Cells

BioLife Solutions, Inc. announced that Cord Blood Registry uses BioLife's CryoStor [3] clinical grade cryopreservation freeze media in its process for cryogenic storage of umbilical cord tissue stem cells. Storage of umbilical cord tissue is a product currently offered by a limited number of cord blood banks throughout the world. While umbilical cord blood is a source of hematopoietic (blood) stem cells, umbilical cord tissue is a rich source of mesenchymal stem cells, which have the ability to differentiate into cells of the connective tissue including osteoblasts (bone-forming cells), chondrocytes (cartilage cells), and adipocytes (fat cells).

BioLife Solutions, Inc. Announces Preliminary Revenue Results for the First Quarter Ended March 31, 2015

BioLife Solutions, Inc. announced preliminary revenue results for the first quarter ended March 31, 2015. The company announced preliminary revenue of $1.5 million for the first quarter of 2015 comprised entirely of core proprietary product revenue, representing 30% growth over the same period of 2014. Proprietary revenue growth was driven by a 92% year over year increase from customers in the regenerative medicine segment. Several new regenerative medicine customers commenced product evaluations in the quarter and others started using CryoStor and HypoThermosol to preserve cell-based therapeutics in clinical trials focused on various cancers including leukemia, melanoma, renal cancer, liver cancer, as well as limb ischemia and dermal defects.

BioLife Solutions, Inc. Announces Cardio3 BioSciences

BioLife Solutions, Inc. announced that Cardio3 BioSciences has embedded the company's clinical grade CryoStor cryopreservation freeze media in its ongoing Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) phase III clinical trial in Europe and Israel and the pending CHART-2 phase III clinical trial to be conducted in the United States. CHART-1 (Congestive Heart Failure Cardiopoietic Regenerative Therapy) is a patient prospective, controlled multi-centre, randomized, double-blinded Phase III clinical trial comparing treatment with C-Cure to a sham treatment. The trial has recruited 240 patients with chronic advanced symptomatic heart failure. The primary endpoint of the trial is a composite endpoint including mortality, morbidity, quality of life, Six Minute Walk Test and left ventricular structure and function at nine months post-procedure.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLFS:US $2.07 USD +0.0298

BLFS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Sigma-Aldrich Corp $138.61 USD +0.22
View Industry Companies

Industry Analysis


Industry Average

Valuation BLFS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.0x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOLIFE SOLUTIONS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at